RIGL
Rigel Pharmaceuticals

12,356
Loading...
Loading...
News
all
press releases
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·18h ago
News Placeholder
More News
News Placeholder
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Zacks·2d ago
News Placeholder
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
Zacks·9d ago
News Placeholder
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
Zacks·16d ago
News Placeholder
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·18d ago
News Placeholder
Do Options Traders Know Something About RIGL Stock We Don't?
Investors need to pay close attention to Rigel Pharmaceuticals stock based on the movements in the options market lately.
Zacks·22d ago
News Placeholder
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Zacks·1mo ago
News Placeholder
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
News Placeholder
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Zacks·1mo ago
News Placeholder
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Zacks·1mo ago

Latest RIGL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.